NEW YORK – To date, most of the predictive tools for precision oncology have been focused on identifying patients likely to respond to targeted therapies. The field has made great strides when it comes to identifying and inhibiting molecular features driving patients' cancer cells.
The same has not been true, however, for identifying patients likely to respond to many chemotherapy agents, which are commonly their first-line options.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
